What is HC Wainwright's Forecast for TRVI FY2030 Earnings?

Key Points

• HC Wainwright lowered its FY2030 EPS forecast for Trevi Therapeutics to $0.65 from $0.70, while maintaining a Buy rating and a $24 price target.
• Analyst sentiment remains broadly positive: Trevi has an average Buy rating and a consensus price target of $26.75, with recent targets ranging from $23 to $40.
• Trevi shares opened at $17.80, compared with a 12-month range of $6.93 to $20.22; the company’s latest quarterly loss of $0.11 per share matched consensus expectations.

Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) - HC Wainwright dropped their FY2030 earnings per share (EPS) estimates for Trevi Therapeutics in a research report issued to clients and investors on Tuesday, August 11th. HC Wainwright analyst B. Folkes now expects that the company will post earnings per share of $0.65 for the year, down from their previous forecast of $0.70. HC Wainwright has a "Buy" rating and a $24.00 price target on the stock. The consensus estimate for Trevi Therapeutics' current full-year earnings is ($0.48) per share.

Several other equities analysts have also recently issued reports on the stock. BMO Capital Markets began coverage on shares of Trevi Therapeutics in a research note on Monday, July 20th. They issued an "outperform" rating and a $36.00 target price for the company. B. Riley Financial raised their price target on shares of Trevi Therapeutics from $21.00 to $31.00 and gave the company a "buy" rating in a research report on Monday, July 20th. Oppenheimer lifted their price objective on shares of Trevi Therapeutics from $24.00 to $25.00 and gave the company an "outperform" rating in a report on Friday. Morgan Stanley reaffirmed an "overweight" rating and issued a $23.00 price objective on shares of Trevi Therapeutics in a report on Friday. Finally, Raymond James Financial reiterated a "strong-buy" rating and issued a $40.00 price objective on shares of Trevi Therapeutics in a research report on Friday. Two research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Trevi Therapeutics currently has an average rating of "Buy" and a consensus price target of $26.75.

Trevi Therapeutics Price Performance

Shares of NASDAQ TRVI opened at $17.80 on Wednesday. The stock has a market capitalization of $2.54 billion, a price-to-earnings ratio of -52.35 and a beta of 1.03. Trevi Therapeutics has a 12 month low of $6.93 and a 12 month high of $20.22. The firm's 50 day simple moving average is $17.13 and its 200-day simple moving average is $14.13.

Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.11) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.11).

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Russell Investments Group Ltd. lifted its position in shares of Trevi Therapeutics by 194.5% during the 2nd quarter. Russell Investments Group Ltd. now owns 4,536 shares of the company's stock valued at $25,000 after buying an additional 2,996 shares in the last quarter. KBC Group NV purchased a new stake in Trevi Therapeutics in the 1st quarter worth $29,000. Hilton Head Capital Partners LLC purchased a new stake in Trevi Therapeutics in the 4th quarter worth $40,000. Caitong International Asset Management Co. Ltd acquired a new position in Trevi Therapeutics during the fourth quarter worth $50,000. Finally, Strs Ohio acquired a new position in Trevi Therapeutics during the first quarter worth $52,000. 95.76% of the stock is owned by institutional investors and hedge funds.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.

Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source